INSIGHTS ON CLINICAL TRIAL DESIGN

• Rethinking Trial Access Through Trust-Driven Design And Local Collaboration

  Locally embedded research models help sponsors reach underserved populations while reducing burden on patients and health systems alike.

• Speed Kills: When Timelines Trump Science In Neuropsychiatric Trials

  This Bold Conversation brings together experts helping to define the next chapter of psychedelic clinical research to unpack lessons from recent regulatory reviews and explore what clinical teams need now.

• How Protocol Design Decisions Shape Recruitment, Data Quality & Study Startup

  Protocol design directly affects recruitment, data quality, and startup speed. Clear workflows, streamlined criteria, and early alignment reduce delays, amendments, and improve reliable study execution.

• Key Takeaways From ADCs In Oncology Trials Webinar

  By aligning cutting-edge design with evolving regulatory expectations, sponsors can unlock the full therapeutic potential of ADCs and deliver transformative cancer treatments to patients worldwide.

• Developing And Validating Clinical Receptor Occupancy Pharmacodynamic Biomarker Assays

  9/25/2025

  Receptor occupancy (RO) assays assess drug-target engagement and support PK/PD modeling. Accurate RO requires customized assays using stabilized blood to monitor CD6 modulation in autoimmune therapy.

• Has Your Clinical Trial Outgrown Its RTSM Software? Here's What to Watch For

  3/25/2026

  This clip explores how rigid RTSM systems push teams into risky manual workarounds and highlights why flexible, adaptable technology is essential when studies evolve and operational demands shift.

• ICH E6(R3): 10 FAQ On What Changed And What It Means For Your Trials

  9/18/2025

  The ICH E6(R3) updated guidelines present 10 critical changes to make clinical trials more efficient, adaptable, and patient-centric, while upholding the standards of scientific and ethical integrity.

• The Neural Crystal Ball: Forecasting Future CNS Drug Development

  4/15/2026

  Advances in the industry are redefining how we treat neurological and psychiatric disorders. In this presentation, Dr. Beatrice Setnik examines the trends and innovations shaping the next generation of therapies.

• Digital Physical Activity Measures In Phase 3 Immunology Trials

  2/25/2025

  Dr. Jie Shen, Research Fellow and Director of Digital Science at AbbVie, shares lessons learned from incorporating digital measures of physical activity into Phase 3 immunology clinical trials.